JANX

Janux Therapeutics, Inc.

Price Chart

Latest Quote

$14.58

-0.06 (-0.41%)

Current Price

Previous Close	$14.64
Open	$14.62
Day High	$15.31
Day Low	$14.50
Volume	6,246,748

Fetched: 2026-06-26T02:12:44

Stock Information

Shares Outstanding	60.98M
Total Debt	$21.57M
Cash Equivalents	$956.39M
Revenue	$13.73M
Net Income	$-114.48M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$889.15M
EPS (TTM)	$-1.84
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$-45.66M
Sales	$13.73M
Income	$-114.48M
Book/sh	$15.47
Cash/sh	$15.68
Employees	108

Financial Ratios

Quick Ratio	16.95
Current Ratio	17.01
Debt/Eq	2.29

Returns & Margins

ROA	-9.44%
ROE	-11.72%
Operating Margin	-916.50%

Ownership

Insider Ownership	6.61%
Institutional Ownership	102.66%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-5.40
P/S	64.75
P/B	0.94

Analyst Data

Recommendation	none
Target Price	$37.19

Technical Indicators

SMA20	$14.00
SMA50	$14.38
SMA200	$17.86
RSI	61.71
ATR	0.6168

Shares Float	39.12M
Short Float	17.00%
Short Ratio	8.22
Volatility	2.52
Rel Volume	5.33

Performance History

Week	+3.04%
Month	+1.25%
Quarter	+5.65%
6 Months	+3.48%
YTD	+6.81%
Year	-37.56%
3 Years	+18.06%
5 Years	-21.86%
10 Years	-42.03%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-25	$14.58	6,246,748
2026-06-24	$14.64	1,492,500
2026-06-23	$14.91	1,188,600
2026-06-22	$14.34	911,700
2026-06-18	$14.22	1,251,100
2026-06-17	$14.15	1,931,800
2026-06-16	$13.70	617,100
2026-06-15	$13.74	574,000
2026-06-12	$13.56	860,400
2026-06-11	$13.66	1,007,100
2026-06-10	$13.15	932,100
2026-06-09	$13.62	507,600
2026-06-08	$13.51	640,000
2026-06-05	$13.36	490,600
2026-06-04	$13.76	621,000
2026-06-03	$13.59	688,800
2026-06-02	$13.78	704,400
2026-06-01	$14.41	725,800
2026-05-29	$14.59	1,051,900
2026-05-28	$14.74	1,010,400
2026-05-27	$14.44	1,720,200
2026-05-26	$14.40	364,600

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

📰 Latest News

Akari Therapeutics Highlights 1st ASCO Abstract Acceptance

IPO-Edge.com • 2026-05-28T22:33:46Z

VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC

Exec Edge • 2026-05-28T16:53:50Z

Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know

Zacks • 2026-05-28T13:55:02Z

Here's Why You Should Add JANX Stock to Your Portfolio Now

Zacks • 2026-05-26T15:28:00Z

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch

Motley Fool • 2026-05-23T20:48:41Z

This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%

Motley Fool • 2026-05-23T20:37:22Z

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Zacks • 2026-05-07T23:05:22Z

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

Zacks • 2026-05-07T13:55:02Z

FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results

BioPharma Dive • 2026-04-28T09:57:00Z

Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool

BioPharma Dive • 2026-04-17T10:04:00Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$10,000,000	$10,588,000	$8,083,000	$8,612,000
Operating Revenue	$10,000,000	$10,588,000	$8,083,000	$8,612,000
Expenses
Total Expenses	$167,667,000	$109,435,000	$81,062,000	$75,703,000
Net Non Operating Interest Income Expense	$44,042,000	$29,853,000	$14,686,000	$4,032,000
Operating Expense	$167,667,000	$109,435,000	$81,062,000	$75,703,000
General And Administrative Expense	$41,771,000	$41,047,000	$26,140,000	$22,262,000
Interest Expense	-	-	-	-
Interest Expense Non Operating	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-113,625,000	$-68,994,000	$-58,293,000	$-63,059,000
Net Interest Income	$44,042,000	$29,853,000	$14,686,000	$4,032,000
Interest Income	$44,042,000	$29,853,000	$14,686,000	$4,032,000
Normalized Income	$-113,625,000	$-68,994,000	$-58,293,000	$-63,059,000
Net Income From Continuing And Discontinued Operation	$-113,625,000	$-68,994,000	$-58,293,000	$-63,059,000
Total Operating Income As Reported	$-157,667,000	$-98,847,000	$-72,979,000	$-67,091,000
Net Income Common Stockholders	$-113,625,000	$-68,994,000	$-58,293,000	$-63,059,000
Net Income	$-113,625,000	$-68,994,000	$-58,293,000	$-63,059,000
Net Income Including Noncontrolling Interests	$-113,625,000	$-68,994,000	$-58,293,000	$-63,059,000
Net Income Continuous Operations	$-113,625,000	$-68,994,000	$-58,293,000	$-63,059,000
Pretax Income	$-113,625,000	$-68,994,000	$-58,293,000	$-63,059,000
Interest Income Non Operating	$44,042,000	$29,853,000	$14,686,000	$4,032,000
Operating Income	$-157,667,000	$-98,847,000	$-72,979,000	$-67,091,000
Per Share
Diluted EPS	$-1.83	$-1.28	$-1.32	$-1.52
Basic EPS	$-1.83	$-1.28	$-1.32	$-1.52
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-155,638,000	$-96,787,000	$-71,024,000	$-66,250,000
Reconciled Depreciation	$2,029,000	$2,060,000	$1,955,000	$841,000
EBITDA (Bullshit earnings)	$-155,638,000	$-96,787,000	$-71,024,000	$-66,250,000
EBIT	$-157,667,000	$-98,847,000	$-72,979,000	$-67,091,000
Diluted Average Shares	$61,966,999	$53,751,480	$44,016,283	$41,469,631
Basic Average Shares	$61,966,999	$53,751,480	$44,016,283	$41,469,631
Diluted NI Availto Com Stockholders	$-113,625,000	$-68,994,000	$-58,293,000	$-63,059,000
Research And Development	$125,896,000	$68,388,000	$54,922,000	$53,441,000
Selling General And Administration	$41,771,000	$41,047,000	$26,140,000	$22,262,000
Other Gand A	$41,771,000	$41,047,000	$26,140,000	$22,262,000

Fetched: 2026-06-25

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$956,822,000	$1,022,781,000	$344,349,000	$320,740,000
Total Assets	$1,001,565,000	$1,061,516,000	$380,407,000	$364,010,000
Total Non Current Assets	$25,678,000	$27,850,000	$31,166,000	$31,571,000
Other Non Current Assets	$3,424,000	$3,700,000	$3,325,000	$2,206,000
Current Assets	$975,887,000	$1,033,666,000	$349,241,000	$332,439,000
Prepaid Assets	$2,892,000	$3,112,000	$3,052,000	-
Receivables	$6,428,000	$5,381,000	$2,161,000	-
Accrued Interest Receivable	$6,428,000	$5,381,000	$2,161,000	-
Cash Cash Equivalents And Short Term Investments	$966,567,000	$1,025,173,000	$344,028,000	$327,016,000
Cash And Cash Equivalents	$52,334,000	$430,605,000	$19,205,000	$51,426,000
Other Current Assets	-	-	$5,213,000	$5,423,000
Accounts Receivable	-	-	-	-
Debt
Total Debt	$22,139,000	$23,025,000	$24,542,000	$25,305,000
Long Term Debt And Capital Lease Obligation	$19,746,000	$21,276,000	$23,025,000	$24,542,000
Current Debt And Capital Lease Obligation	$2,393,000	$1,749,000	$1,517,000	$763,000
Liabilities
Total Liabilities Net Minority Interest	$44,743,000	$38,735,000	$36,058,000	$43,270,000
Total Non Current Liabilities Net Minority Interest	$19,746,000	$21,276,000	$23,025,000	$26,763,000
Current Liabilities	$24,997,000	$17,459,000	$13,033,000	$16,507,000
Payables And Accrued Expenses	$18,014,000	$11,144,000	$6,508,000	$7,667,000
Payables	$4,971,000	$4,026,000	$2,424,000	$2,159,000
Accounts Payable	$4,971,000	$4,026,000	$2,424,000	$2,159,000
Current Deferred Liabilities	-	$0	$1,705,000	$5,406,000
Non Current Deferred Liabilities	-	-	$0	$2,221,000
Other Current Liabilities	-	-	-	$169,000
Equity
Common Stock Equity	$956,822,000	$1,022,781,000	$344,349,000	$320,740,000
Total Equity Gross Minority Interest	$956,822,000	$1,022,781,000	$344,349,000	$320,740,000
Stockholders Equity	$956,822,000	$1,022,781,000	$344,349,000	$320,740,000
Gains Losses Not Affecting Retained Earnings	$4,316,000	$2,163,000	$665,000	$-1,535,000
Other Equity Adjustments	$4,316,000	$2,163,000	$665,000	$-1,535,000
Retained Earnings	$-351,382,000	$-237,757,000	$-168,763,000	$-110,470,000
Preferred Securities Outside Stock Equity	-	-	-	-
Other
Ordinary Shares Number	$60,384,283	$59,064,606	$46,252,440	$41,616,260
Share Issued	$60,384,283	$59,064,606	$46,252,440	$41,616,260
Tangible Book Value	$956,822,000	$1,022,781,000	$344,349,000	$320,740,000
Invested Capital	$956,822,000	$1,022,781,000	$344,349,000	$320,740,000
Working Capital	$950,890,000	$1,016,207,000	$336,208,000	$315,932,000
Capital Lease Obligations	$22,139,000	$23,025,000	$24,542,000	$25,305,000
Total Capitalization	$956,822,000	$1,022,781,000	$344,349,000	$320,740,000
Additional Paid In Capital	$1,303,828,000	$1,258,316,000	$512,401,000	$432,703,000
Capital Stock	$60,000	$59,000	$46,000	$42,000
Common Stock	$60,000	$59,000	$46,000	$42,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$19,746,000	$21,276,000	$23,025,000	$24,542,000
Current Capital Lease Obligation	$2,393,000	$1,749,000	$1,517,000	$763,000
Pensionand Other Post Retirement Benefit Plans Current	$4,590,000	$4,566,000	$3,303,000	$2,671,000
Current Accrued Expenses	$13,043,000	$7,118,000	$4,084,000	$5,508,000
Net PPE	$22,254,000	$24,150,000	$27,841,000	$29,365,000
Accumulated Depreciation	$-6,967,000	$-4,952,000	$-2,914,000	$-972,000
Gross PPE	$29,221,000	$29,102,000	$30,755,000	$30,337,000
Other Properties	$27,719,000	$27,652,000	$29,335,000	$29,117,000
Machinery Furniture Equipment	$1,502,000	$1,450,000	$1,420,000	$1,075,000
Other Short Term Investments	$914,233,000	$594,568,000	$324,823,000	$275,590,000
Current Deferred Revenue	-	$0	$1,705,000	$5,406,000
Non Current Deferred Revenue	-	-	$0	$2,221,000
Construction In Progress	-	-	$43,000	$145,000
Treasury Shares Number	-	-	-	-

Fetched: 2026-06-25

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-83,278,000	$-44,173,000	$-52,425,000	$-49,367,000
Operating Activities
Operating Cash Flow	$-82,235,000	$-43,814,000	$-50,575,000	$-42,922,000
Cash Flow From Continuing Operating Activities	$-82,235,000	$-43,814,000	$-50,575,000	$-42,922,000
Operating Gains Losses	-	-	-	-
Investing Activities
Capital Expenditure	$-1,043,000	$-359,000	$-1,850,000	$-6,445,000
Investing Cash Flow	$-300,981,000	$-258,021,000	$-41,194,000	$58,266,000
Cash Flow From Continuing Investing Activities	$-300,981,000	$-258,021,000	$-41,194,000	$58,266,000
Financing Activities
Repurchase Of Capital Stock	$-347,000	-	-	-
Financing Cash Flow	$4,945,000	$713,235,000	$59,548,000	$500,000
Cash Flow From Continuing Financing Activities	$4,945,000	$713,235,000	$59,548,000	$500,000
Net Common Stock Issuance	$-347,000	$698,267,000	$56,530,000	$0
Issuance Of Capital Stock	-	$698,267,000	$56,530,000	$0
Common Stock Issuance	-	$698,267,000	$56,530,000	$0
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
End Cash Position	$53,150,000	$431,421,000	$20,021,000	$52,242,000
Beginning Cash Position	$431,421,000	$20,021,000	$52,242,000	$36,398,000
Changes In Cash	$-378,271,000	$411,400,000	$-32,221,000	$15,844,000
Proceeds From Stock Option Exercised	$5,292,000	$14,968,000	$3,018,000	$500,000
Common Stock Payments	$-347,000	-	-	-
Net Investment Purchase And Sale	$-299,938,000	$-257,662,000	$-39,344,000	$64,711,000
Sale Of Investment	$405,284,000	$212,915,000	$278,000,000	$359,100,000
Purchase Of Investment	$-705,222,000	$-470,577,000	$-317,344,000	$-294,389,000
Net PPE Purchase And Sale	$-1,043,000	$-359,000	$-1,850,000	$-6,445,000
Purchase Of PPE	$-1,043,000	$-359,000	$-1,850,000	$-6,445,000
Change In Working Capital	$6,714,000	$685,000	$-6,554,000	$4,276,000
Change In Other Working Capital	$-2,000	$-1,670,000	$-5,244,000	$5,053,000
Change In Other Current Assets	$276,000	$-375,000	$-1,119,000	$-1,270,000
Change In Payables And Accrued Expense	$7,267,000	$6,010,000	$-401,000	$3,862,000
Change In Accrued Expense	$6,290,000	$4,426,000	$-678,000	$4,156,000
Change In Payable	$977,000	$1,584,000	$277,000	$-294,000
Change In Account Payable	$977,000	$1,584,000	$277,000	$-294,000
Change In Prepaid Assets	$-827,000	$-3,280,000	$210,000	$-3,369,000
Stock Based Compensation	$40,221,000	$33,020,000	$20,005,000	$17,203,000
Amortization Of Securities	$-17,574,000	$-10,585,000	$-7,688,000	$-2,183,000
Depreciation Amortization Depletion	$2,029,000	$2,060,000	$1,955,000	$841,000
Depreciation And Amortization	$2,029,000	$2,060,000	$1,955,000	$841,000
Depreciation	$2,029,000	$2,060,000	$1,955,000	$841,000
Net Income From Continuing Operations	$-113,625,000	$-68,994,000	$-58,293,000	$-63,059,000
Change In Receivables	-	-	-	$0
Changes In Account Receivables	-	-	-	$0
Issuance Of Debt	-	-	-	-
Net Issuance Payments Of Debt	-	-	-	-
Net Long Term Debt Issuance	-	-	-	-
Long Term Debt Issuance	-	-	-	-

Fetched: 2026-06-25